Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.

Zugazagoitia J, Gómez-Rueda A, Jantus-Lewintre E, Isla D, Camps C, Ramos I, Trigo JM, Bernabé R, Juan-Vidal O, Sanchez-Torres JM, García-Campelo R, Provencio M, Felip E, de Castro J, Faull I, Lanman RB, Ponce-Aix S, Paz-Ares L, Garrido P.

Lung Cancer. 2019 Aug;134:72-78. doi: 10.1016/j.lungcan.2019.05.032. Epub 2019 May 30.

PMID:
31319999
2.

Immune Checkpoint Inhibitor-Associated Pericarditis.

Altan M, Toki MI, Gettinger SN, Carvajal-Hausdorf DE, Zugazagoitia J, Sinard JH, Herbst RS, Rimm DL.

J Thorac Oncol. 2019 Jun;14(6):1102-1108. doi: 10.1016/j.jtho.2019.02.026. Epub 2019 Mar 7.

PMID:
30851443
3.

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.

Zugazagoitia J, Ramos I, Trigo JM, Palka M, Gómez-Rueda A, Jantus-Lewintre E, Camps C, Isla D, Iranzo P, Ponce-Aix S, García-Campelo R, Provencio M, Franco F, Bernabé R, Juan-Vidal O, Felip E, de Castro J, Sanchez-Torres JM, Faul I, Lanman RB, Garrido P, Paz-Ares L.

Ann Oncol. 2019 Feb 1;30(2):290-296. doi: 10.1093/annonc/mdy512.

PMID:
30535340
4.

KRAS-Mutant non-small cell lung cancer: From biology to therapy.

Ferrer I, Zugazagoitia J, Herbertz S, John W, Paz-Ares L, Schmid-Bindert G.

Lung Cancer. 2018 Oct;124:53-64. doi: 10.1016/j.lungcan.2018.07.013. Epub 2018 Jul 19. Review.

5.

Targeting EGFR in Lung Cancer: Current Standards and Developments.

Díaz-Serrano A, Gella P, Jiménez E, Zugazagoitia J, Paz-Ares Rodríguez L.

Drugs. 2018 Jun;78(9):893-911. doi: 10.1007/s40265-018-0916-4. Review.

PMID:
29915896
6.

Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer.

Zugazagoitia J, Biosca M, Oliveira J, Olmedo ME, Dómine M, Nadal E, Ruffinelli JC, Muñoz N, Luna AM, Hernández B, Martínez M, Gallego I, Martínez de Castro E, Font C, Calvo V, Martínez-Marín V, Corral J, Noguerón E, Mondéjar R, García Escobar I, Salvador-Coloma C, Juan Ó, Sánchez Cánovas M, Valdivia J, Ochoa MP, López Castro R, Obispo B, Pangua C, Sereno M, Fernández Franco L, Mielgo X, Calzas J, Blasco A, Aparisi F, Chara L, Grau JF, Soares M, Gómez A, Zenzola V, García-Morillo M, Cacho D, Díaz-Serrano A, Aguado C, Ponce-Aix S, González-Larriba JL, Muñoz AJ, Lora D, Paz-Ares L, Manzano A.

Eur Respir J. 2018 May 3;51(5). pii: 1702431. doi: 10.1183/13993003.02431-2017. Print 2018 May. No abstract available.

PMID:
29563169
7.

Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials.

Carretero-González A, Lora D, Ghanem I, Zugazagoitia J, Castellano D, Sepúlveda JM, López-Martin JA, Paz-Ares L, de Velasco G.

Oncotarget. 2018 Jan 20;9(9):8706-8715. doi: 10.18632/oncotarget.24283. eCollection 2018 Feb 2.

8.

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.

Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L.

Ann Oncol. 2018 Jan 1;29(suppl_1):i10-i19. doi: 10.1093/annonc/mdx703.

9.

Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.

Zugazagoitia J, Rueda D, Carrizo N, Enguita AB, Gómez-Sánchez D, Díaz-Serrano A, Jiménez E, Mérida A, Calero R, Lujan R, De Miguel E, Gámez P, Díaz-Hellín V, Nuñez JA, Iglesias L, Ferrer I, Paz-Ares L, Ponce-Aix S.

Clin Lung Cancer. 2018 Jan;19(1):65-73.e7. doi: 10.1016/j.cllc.2017.06.008. Epub 2017 Jun 23.

PMID:
28780976
10.

Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib.

Zugazagoitia J, Díaz A, Jimenez E, Nuñez JA, Iglesias L, Ponce-Aix S, Paz-Ares L.

Front Med (Lausanne). 2017 Apr 5;4:36. doi: 10.3389/fmed.2017.00036. eCollection 2017. Review.

11.

Biological therapies in nonsmall cell lung cancer.

Zugazagoitia J, Molina-Pinelo S, Lopez-Rios F, Paz-Ares L.

Eur Respir J. 2017 Mar 2;49(3). pii: 1601520. doi: 10.1183/13993003.01520-2016. Print 2017 Mar. Review.

12.

Osimertinib in EGFR-mutant NSCLC: how to select patients and when to treat.

Zugazagoitia J, Ferrer I, Paz-Ares L.

Lancet Oncol. 2016 Dec;17(12):1622-1623. doi: 10.1016/S1470-2045(16)30506-X. Epub 2016 Oct 14. No abstract available.

PMID:
27751845
13.

Current Challenges in Cancer Treatment.

Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L.

Clin Ther. 2016 Jul;38(7):1551-66. doi: 10.1016/j.clinthera.2016.03.026. Epub 2016 May 2. Review.

PMID:
27158009
14.

Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

Cedrés S, Ponce-Aix S, Pardo-Aranda N, Navarro-Mendivil A, Martinez-Marti A, Zugazagoitia J, Sansano I, Montoro MA, Enguita A, Felip E.

Lung Cancer. 2016 Jun;96:1-6. doi: 10.1016/j.lungcan.2016.03.001. Epub 2016 Mar 10.

PMID:
27133741
15.

Necitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?

Zugazagoitia J, Ponce S, Paz-Ares L.

Transl Lung Cancer Res. 2016 Feb;5(1):95-7. doi: 10.3978/j.issn.2218-6751.2015.08.05. No abstract available.

16.

Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martinez P, Felip E.

PLoS One. 2015 Mar 16;10(3):e0121071. doi: 10.1371/journal.pone.0121071. eCollection 2015.

17.

The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects.

Zugazagoitia J, Enguita AB, Nuñez JA, Iglesias L, Ponce S.

J Thorac Dis. 2014 Oct;6(Suppl 5):S526-36. doi: 10.3978/j.issn.2072-1439.2014.01.27. Review.

18.

Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.

Zugazagoitia J, Pérez-Segura P, Manzano A, Blanco I, Vega A, Custodio A, Teulé A, Fachal L, Martínez B, González-Sarmiento R, Cruz-Hernández JJ, Chirivella I, Garcés V, Garre P, Romero A, Caldés T, Díaz-Rubio E, de la Hoya M.

Breast Cancer Res Treat. 2014 Nov;148(2):415-21. doi: 10.1007/s10549-014-3167-4. Epub 2014 Oct 24.

PMID:
25342642
19.

Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.

Zugazagoitia J, Puente J, González-Larriba JL, Manzano A, Sotelo M, Hernández S, Sanz J, Pérez P, Díaz-Rubio E.

Oncology. 2013;84(5):255-64. doi: 10.1159/000346534. Epub 2013 Feb 20.

PMID:
23428780
20.

Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function.

Zugazagoitia J, Manzano A, Sastre J, Ladero JM, Puente J, Díaz-Rubio E.

Clin Transl Oncol. 2013 Feb;15(2):146-53. doi: 10.1007/s12094-012-0902-3. Epub 2012 Aug 9.

PMID:
22875650
21.

Severe perirenal hematoma in a patient with a single kidney treated with sunitinib for metastatic pancreatic neuroendocrine tumor.

Zugazagoitia J, Sastre J, Barrera J, García B, Díaz-Rubio E.

J Cancer Res Ther. 2012 Apr-Jun;8(2):303-5. doi: 10.4103/0973-1482.98997.

22.
23.

Excited-state dynamics of nitrated push-pull molecules: the importance of the relative energy of the singlet and triplet manifolds.

Collado-Fregoso E, Zugazagoitia JS, Plaza-Medina EF, Peon J.

J Phys Chem A. 2009 Dec 3;113(48):13498-508. doi: 10.1021/jp905379y.

PMID:
19839627
24.

Relaxation in the triplet manifold of 1-nitronaphthalene observed by transient absorption spectroscopy.

Zugazagoitia JS, Collado-Fregoso E, Plaza-Medina EF, Peon J.

J Phys Chem A. 2009 Feb 5;113(5):805-10. doi: 10.1021/jp8087397.

PMID:
19140711
25.

Ultrafast intersystem crossing in 1-nitronaphthalene. An experimental and computational study.

Zugazagoitia JS, Almora-Díaz CX, Peon J.

J Phys Chem A. 2008 Jan 24;112(3):358-65. doi: 10.1021/jp074809a. Epub 2008 Jan 1.

PMID:
18166024
26.

Excited state intramolecular proton transfer in Schiff bases. Decay of the locally excited enol state observed by femtosecond resolved fluorescence.

Rodríguez-Córdoba W, Zugazagoitia JS, Collado-Fregoso E, Peon J.

J Phys Chem A. 2007 Jul 19;111(28):6241-7. Epub 2007 Jun 21.

PMID:
17583330

Supplemental Content

Loading ...
Support Center